3631 results for «372»

Filter By

3631 results

Mitral TEER intraprocedural guidance

11 Sep 2025 – From PCR Rio Valves 2025

This session offers a detailed exploration of mitral TEER intraprocedural guidance through case-based learning. It highlights step-by-step techniques, including post-processing and key questions interventionalists face regarding residual regurgitation, clip insertion, and evaluating final procedural outcomes.

EuroPCR 2025 Closing Ceremony

23 May 2025 – From EuroPCR 2025

Conclude your conference experience with the EuroPCR 2025 Closing Ceremony, celebrating the achievements, innovations, and advancements presented throughout the event, and setting the stage for future developments in interventional cardiology.

EuroPCR 2025 Closing Ceremony

Jon DeHaan Foundation Award & Michele Pighi Young Investigator Award

21 May 2025 – From EuroPCR 2025

Celebrate innovation and research excellence in interventional cardiology with the Jon DeHaan Foundation Award and Michele Pighi Young Investigator Award session. This session highlights groundbreaking work and emerging talent shaping the future of cardiovascular interventions.

Jon DeHaan Foundation Award & Michele Pighi Young Investigator Award

Coronary sinus reducer for microvascular angina

28 Feb 2020

A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...

Coronary sinus reducer for microvascular angina

EuroPCR 2019 Press Release: A pragmatic approach to defining high bleeding risk for patients undergoing in PCI

22 May 2019

Paris, France, 22 May 2019. Identification and management of patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) is of major importance, but a lack of standardisation in defining this population limits trial design, data interpretation, and clinical decision-making.

A pragmatic approach to defining high bleeding risk for patients undergoing in PCI

Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation – The WATCH-TAVR Trial

26 Oct 2023

Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

Panagiotis Xaplanteris

Author

Panagiotis Xaplanteris
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

EuroPCR 2019 Press Release: Education rhymed with interaction at the world-leading course in interventional cardiovascular medicine

24 May 2019

Paris, France, 24 May 2019. A total of 11,206 participants from over 120 different countries were present at the 30th edition of EuroPCR. An additional 4,700 online learners connected to watch a selection of sessions that were made available both live and on replay via PCR...

Peer-to-peer exchange on daily practice was at a peak throughout the 30th edition of the Course

The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

22 Mar 2022

Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022. 

Daniele Giacoppo

Author

Daniele Giacoppo
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

SCOPE I: A randomized trial of the ACURATE Neo vs. the SAPIEN 3 bioprosthesis in patients with severe aortic stenosis - TCT 2019

28 Sep 2019

The results of the SCOPE I trial were presented at TCT 2019 in San Francisco by Jonas Lanz, Bern University Hospital. Read the analysis by Fabien Praz.

Fabien Praz

Author

Fabien Praz
SCOPE I: A randomized trial of the ACURATE Neo vs. the SAPIEN 3 bioprosthesis in patients with severe aortic stenosis

Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3

02 Apr 2025

Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Kalaivani Mahadevan

Author

Kalaivani Mahadevan
FFR-guided PCI vs CABG: 5-year results of the FAME 3 trial
Didn’t find what you were looking for?